Clovis Oncology (CLVS) Receives FDA Acceptance for IND Application for Oral EGFR Mutant-Selective Inhibitor CO-1686
Tweet
Share
E-mailGet Alerts CLVS Hot Sheet
Join SI Premium – FREE
Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application to begin clinical investigation of CO-1686, a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC).
Initial Phase I/II studies are expected to commence in the U.S. and Europe during the second quarter of 2012 and in Asia during the third quarter of 2012. Following the establishment of the appropriate dose, Clovis intends to study CO-1686 in an expansion cohort of NSCLC patients who have failed either Tarceva® or Iressa® and have developed a secondary mutation, T790M, which is the dominant resistance mechanism to Tarceva and Iressa. Clovis is developing a companion diagnostic in collaboration with its partner Roche Molecular Systems, Inc. to identify patients with the T790M mutation.
Initial Phase I/II studies are expected to commence in the U.S. and Europe during the second quarter of 2012 and in Asia during the third quarter of 2012. Following the establishment of the appropriate dose, Clovis intends to study CO-1686 in an expansion cohort of NSCLC patients who have failed either Tarceva® or Iressa® and have developed a secondary mutation, T790M, which is the dominant resistance mechanism to Tarceva and Iressa. Clovis is developing a companion diagnostic in collaboration with its partner Roche Molecular Systems, Inc. to identify patients with the T790M mutation.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Keenova doses first patient in Phase 3 hammer toe drug trial
- Harrow study shows Iheezo cuts discomfort after eye injections
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
